On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.
ALEXANDRIA, VA, UNITED STATES, February 4, 2025 /EINPresswire / -- The National Psoriasis Foundation (NPF) is pleased to announce an anonymous gift o ...
Tilt Beauty, a groundbreaking new brand specializing in cutting-edge design and clean formulas launches today exclusively at TiltBeauty.com. Tilt Beauty was created to make everyday makeup essentials ...
Hispanic and non-White patients with psoriatic arthritis (PsA) had higher tender joint counts and greater disease severity, highlighting racial and ethnic disparities in PsA disease burden and ...
AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.